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ABSTRACT 
A 20-year-old woman was diagnosed with stage 4 lung adenocarcinoma with an epidermal growth factor receptor 
(EGFR) exon 20 insertion gene mutation. Although the patient underwent chemotherapy, her lesions progressed. 
Liquid biopsy for EGFR T790M mutation showed negative results. After administering osimertinib, reduction of 
the lesions at the primary site was observed, and the patient’s respiratory condition improved. Previous reports 
showing successful treatment of EGFR exon 20 insertion-positive lung adenocarcinoma with the standard osimer-
tinib dose of 80 mg are limited. The present case demonstrated that osimertinib could be a possible treatment 
option for EGFR exon 20 insertion-positive lung adenocarcinoma. 
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INTRODUCTION 
The frequency of exon 20 insertions in the 
epidermal growth factor receptor (EGFR) 
gene has been reported to account for 2.0–
5.8 % of the total EGFR mutations. Accord-
ing to previous reports, non-small cell lung 
cancers with EGFR exon 20 insertions are re-
sistant to EGFR-tyrosine kinase inhibitor 
(TKI) treatment. Only a small number of 
cases have been reported in which osimertinib 
was administered to patients with lung cancer 
who were positive for EGFR exon 20 inser-
tions (Jänne et al., 2015, Piotrowska et al., 
2018, Riess et al., 2017, Veggel et al., 2018). 
There is currently limited research on the ef-
fect of EGFR-TKI on exon 20 insertion posi-
tive non-small cell lung cancer. Osimertinib 
may be an effective treatment for non-small 
cell lung cancer with exon 20 insertions. 
 
CASE REPORT 
A woman in her 20s with no previous his-
tory of smoking was diagnosed with stage 4 
lung adenocarcinoma (cT2aN3M1b) with as-
sociated liver metastasis, multiple bone me-
tastasis, and multiple brain metastasis. Her 
staging was based on the classification of lung 
cancer as per The Japan Lung Cancer Society, 
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7th edition. Gene analysis revealed positive re-
sults for an EGFR exon 20 insertion mutation 
and negative results for an echinoderm micro-
tubule-associated protein-like 4 anaplastic 
lymphoma kinase (EML4-ALK) gene fusion. 
PD-L1 expression in the lung biopsy tissue 
was 80–90 %. 
She received cisplatin and pemetrexed so-
dium hydrate (PEM) chemotherapy. Follow-
ing single-agent PEM chemotherapy admin-
istration, we observed tumor progression and 
an increasing number of cysts in the lung. 
Thoracoscopic lung biopsy revealed multiple 
metastatic lesions in the lung field and cystic 
lesions associated with the check valve mech-
anism containing cancer cells, but no evi-
dence of interstitial pneumonia or vasculitis 
was noted. There were no findings in the la-
boratory data suggesting any collagenous dis-
eases. In September X+1 year, she was ad-
ministered 30 mg of afatinib orally, but ad-
ministration was discontinued after 30 days 
due to hepatic dysfunction. After her hepatic 
function improved, she received 20 mg of 
afatinib; however, a liver function disorder 
was observed 5 days after the afatinib admin-
istration. Due to hepatic dysfunction and dis-
ease progression, afatinib was discontinued. 
In November X+1 year, she received docet-
axel hydrate (DTX) without ramucirumab, 
because of the high risk of bleeding from the 
bronchus. Even though the treatment effects 
of DTX were obtained, her treatment was 
changed to pembrolizumab because it was 
commercially available. However, tumor pro-
gression was observed even though three 
courses of pembrolizumab treatment were ad-
ministered. DTX was administered again 
from June to August X year, and tumor 
growth was still observed despite the total 
eight courses of treatment. In September, the 
patient received one course of amrubicin, but 
it was ineffective. Because of an eating disor-
der, malaise, and breathing difficulty, the pa-
tient was readmitted to the hospital in October 
(2 years from the diagnosis). Blood biochem-
ical examination findings at this time revealed 
the following: leukocyte increased to 
16400/μl (neutrophils, 91.0 %; lymphocytes, 
4.1 %; monocytes, 4.4 %; eosinophils, 
0.10 %; and basophils, 0.40 %), hemoglobin 
level reduced to 10.5 g/dl, C-reactive protein 
level increased to 16.93 mg/dl, and CYFRA 
level increased to 17.94 ng/dl. The results of 
the EGFR mutation plasma test were negative 
for the T790M mutation and positive for the 
exon 20 insertion. Histological examination 
to assess the EGFR mutation could not be per-
formed due to her poor general condition. A 
chest X-ray (Figure 1) revealed a tumor 
shadow in the right hilar area, an invasive 
shadow in the left middle and lower lung 
fields, and pleural effusion on both sides. 
 
Figure 1: Chest X-ray scan revealed a tumor 
shadow in the right hilar area, an invasive 
shadow in the left middle and lower lung 
fields, and pleural effusion on both sides. 
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Computed tomography (CT) (Figure 2) 
revealed tumors in the right middle and lower 
lobes, multiple cystic lesions in the lung field, 
mild pneumothorax of the right lung (Figure 
2a), and pleural effusion on both sides (Figure 
2b). 
After hospitalization, deterioration of her 
respiratory condition and performance status 
(PS) was observed due to disease progression 
(PS=3). A standard dose (80 mg) of osimer-
tinib was administered after explaining the ef-
fects and side effects of the treatment to the 
patient and her family. Respiratory state im-
proved, and PS improved from 3 to 1, approx-
imately 1 week from the introduction of osi-
mertinib; cavitation and decrease in size of 
the primary lesion were observed via CT after
 
 
Figure 2: Computed tomography (CT) scan before administration of osimertinib. Primary lesions in the 
right middle and lower lobes, multiple cystic lesions in the lung field, and mild pneumothorax were ob-
served in the right lung (a). Pleural effusion on both sides was observed (b). 
 
a 
b 
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43 (Figure 3a) and 81 days (Figure 3b), re-
spectively. The maximum effect was judged 
as a partial response (PR). CYFRA level de-
creased to 6.02 ng/dl, and CRP level de-
creased to 0.43 mg/dl at 16 days from the ad-
ministration of osimertinib. Approximately 4 
months after initiating osimertinib treatment, 
her respiratory condition deteriorated due to 
hemoptysis, and the patient died approxi-
mately 2 years and 5 months after the initial 
diagnosis of lung cancer. 
 
 
Figure 3: CT images after administration of osimertinib. Cavitation and decrease in size of the primary 
lesion were observed after 43 (a) and 81 days (b). 
 
 
 
a 
b 
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DISCUSSION 
To the best of our knowledge, there is only 
a small number of case reports that demon-
strate successful treatment of EGFR exon 20 
insertion-positive lung adenocarcinoma with 
a standard osimertinib dose of 80 mg (Jänne 
et al., 2015, Piotrowska et al., 2018, Riess et 
al., 2017, Veggel et al., 2018). Exon 19 dele-
tion mutations and exon 21 L858R mutations 
constitute approximately 90 % of EGFR mu-
tations (Beau-Faller et al., 2014). Other gene 
mutations, generally known as uncommon 
mutations such as E709X, G719X, S768I, 
P848L, L861Q, and exon 20 insertions, are lo-
cated in exons 18–21. Exon 20 insertions have 
been reported in 2.0–5.8 % of EGFR mutation 
cases; such cases are considered to be re-
sistant to EGFR-TKI (Kobayashi and 
Mitsudomi, 2016; Yasuda et al., 2012). In 
previous reports, one patient with exon 20 in-
sertions received 40 mg osimertinib in the 
AURA test (Phase I), but disease progression 
was observed (Jänne et al., 2015). Two other 
reports showed partial responses with 160 mg 
osimertinib used for treating patients with 
exon 20 positive insertions (Piotrowska et al., 
2018; Riess et al., 2017). However, interstitial 
pneumonia was observed, and therefore, ad-
ministration was discontinued (Riess et al., 
2017). In 2018, Veggel et al. reported the 
standard dose effect of osimertinib for pa-
tients with EGFR exon 20 insertion-positive 
non-small-cell lung cancer (Veggel et al., 
2018). They observed only one patient with 
partial response. The objective response rate 
was reported to be 6 %. 
Several genetic variants have been re-
ported in EGFR exon 20 insertion mutations 
(Kobayashi and Mitsudomi, 2016; Oxnard et 
al., 2013; Yasuda et al., 2012, 2013). Genetic 
variants sensitive to first-generation EGFR-
TKIs have also been observed (Kobayashi 
and Mitsudomi, 2016). Although the gene 
mutation type of exon 20 insertions in this 
case is unknown, we believe that it is not a 
type of mutation that demonstrates the effects 
of first-generation EGFR-TKIs. Hirano et al. 
examined the effect of EGFR-TKI on culture 
cell lines transfected with exon 20 insertion 
mutations. The IC50 value of osimertinib was 
lower than that of other EGFR-TKIs in any 
cell lines. For exon 20 insertions, it is sug-
gested that osimertinib may be more effective 
than other EGFR-TKIs (Hirano et al., 2015). 
In this case, afatinib was administered only 
for 1 month due to liver dysfunction; owing to 
a short period of afatinib administration, the 
effect was not observed. The T790M muta-
tion was not detected via the plasma test be-
fore the administration of osimertinib. Alt-
hough tissue specimens could not be studied 
immediately before administering osimer-
tinib, we believe that a possible T790M mu-
tation being induced by afatinib is very low. 
Although exon 20 insertions are known to 
be resistant to EGFR-TKIs, osimertinib may 
be effective. Clinical trials are currently un-
derway to examine the effects of several 
EGFR-TKIs on non-small cell lung cancer 
positivity for exon 20 insertion mutations 
(UMIN000031929, ClinicalTrials.gov Identi-
fier: NCT03066206, ClinicalTrials.gov Iden-
tifier: NCT03414814). We hope that these re-
sults will establish evidence that osimertinib 
and other EGFR-TKIs are effective for non-
small cell lung cancer positivity for exon 20 
insertion mutations. 
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